Umbilical cord-derived mesenchymal stromal cells for severe COVID-19 ARDS show qualitative improvement and tolerability.

This evidence summary evaluates the use of freshly cultured umbilical cord-derived mesenchymal stromal cells in patients with severe COVID-19 acute respiratory distress syndrome. The study design is identified as a Randomized Controlled Trial, though the publication type is noted as a Review or Summary of Trials. The trial phase was noted as Phase 1 and Phase 2b. The total sample size enrolled in the analysis was 37 participants. The setting for the study was not reported in the available data.

Participants received the intervention of freshly cultured umbilical cord-derived mesenchymal stromal cells. The comparator used in this trial was not reported. The follow-up duration for assessing outcomes was 6 months. Primary outcomes were not reported in the provided summary. Secondary outcomes included the resolution of lymphopenia and patient-reported quality-of-life measures using the SF-36 instrument.

Main results indicated qualitative improvement in all clinical outcomes. Specifically, there was resolution of lymphopenia observed in the cohort. Patient-reported quality-of-life measures showed significant improvement. However, effect sizes, absolute numbers, and p-values or confidence intervals were not reported. The direction of effect was noted as improvement for clinical outcomes and quality of life.

Regarding safety, the intervention was described as well tolerated. Adverse events, serious adverse events, and discontinuations were not reported. There were no specific limitations listed in the provided text. Funding sources and conflicts of interest were also not reported.

Practice relevance is not reported. The evidence suggests potential benefits in lymphopenia resolution and quality of life. However, the lack of statistical data and safety reporting limits definitive conclusions. Clinicians should interpret these findings cautiously given the incomplete reporting of statistical significance and safety profiles. Further research is required to establish efficacy and safety standards.